Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H22O2 |
Molecular Weight | 270.3661 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4
InChI
InChIKey=DNXHEGUUPJUMQT-CBZIJGRNSA-N
InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
DescriptionSources: http://www.drugfuture.com/chemdata/estrone.html | http://pubs.acs.org/doi/abs/10.1021/ja01159a529?journalCode=jacsat | http://pubs.acs.org/doi/abs/10.1021/ja00536a023https://www.ncbi.nlm.nih.gov/pubmed/27960570 | https://www.accessdata.fda.gov/cdrh_docs/pdf/K970915.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83dd22a0-7c59-11e6-84ff-424c58303031Curator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00655
https://www.ncbi.nlm.nih.gov/pubmed/2011412
https://www.ncbi.nlm.nih.gov/pubmed/17943537
Sources: http://www.drugfuture.com/chemdata/estrone.html | http://pubs.acs.org/doi/abs/10.1021/ja01159a529?journalCode=jacsat | http://pubs.acs.org/doi/abs/10.1021/ja00536a023https://www.ncbi.nlm.nih.gov/pubmed/27960570 | https://www.accessdata.fda.gov/cdrh_docs/pdf/K970915.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83dd22a0-7c59-11e6-84ff-424c58303031
Curator's Comment: description was created based on several sources, including
http://www.drugbank.ca/drugs/DB00655
https://www.ncbi.nlm.nih.gov/pubmed/2011412
https://www.ncbi.nlm.nih.gov/pubmed/17943537
Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. It’s used as hameopatic in management of premenopausal and postmenopausal symptoms. In 1929, Butenandt isolated estrone from the urine of pregnant women. Estrone is known to be a carcinogen for human females as well as a cause of breast tenderness or pain, nausea, headache, hypertension, and leg cramps in the context of non-endogenous exposure. In men, estrone has been known to cause anorexia, nausea, vomiting, and erectile dysfunction. Estrone is relevant to health and disease states because of its conversion to estrone sulfate, a long-lived derivative. Estrone sulfate acts as a reservoir that can be converted as needed to the more active estradiol.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11105986
Curator's Comment: Estrone sulfate crossed the blood brain barrier in rats.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01159a529?journalCode=jacsathttps://www.ncbi.nlm.nih.gov/pubmed/22469359
Curator's Comment: Estrone is one of the hormones responsible for sexual development and function in females.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 |
7.0 nM [EC50] | ||
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2011412 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Primary | Estragyn Approved UseEstragyn Vaginal Cream is prescribed in the treatment of menopausal and post menopausal symptoms.
Estragyn Vaginal Cream should be prescribed with an appropriate dosage of a progestin for women with intact uteri to prevent endometrial hyperplasia/carcinoma. |
|||
Primary | Estragyn Approved UseEstragyn Vaginal Cream is prescribed in the treatment of menopausal and post menopausal symptoms.
Estragyn Vaginal Cream should be prescribed with an appropriate dosage of a progestin for women with intact uteri to prevent endometrial hyperplasia/carcinoma. |
|||
Primary | THEELIN Approved UseFor management of Menopausal and postmenopausal disorders |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
733 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/908445/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
550 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/908445/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/908445/ |
0.5 mg single, vaginal dose: 0.5 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ESTRONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15290871/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
no | ||||
weak | ||||
weak | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | weak (co-administration study) Comment: Coadministration with ketoconazole (CYP3A4 inhibitor) resulted in estrone expsoure increase of ~1.4 foold Sources: https://pubmed.ncbi.nlm.nih.gov/9625734/ |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Atheroprotective effect of estriol and estrone sulfate on human vascular smooth muscle cells. | 2000 Jan-Feb |
|
Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. | 2001 |
|
15-ketodihydro-PGF2 alpha, progesterone and cortisol profiles in heifers after induction of parturition by injection of dexamethasone. | 2001 |
|
Estrone, but not 17 beta-estradiol, attenuates kainate-induced seizures and toxicity in male mice. | 2001 |
|
Potential fertility--defining the window of opportunity. | 2001 |
|
Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. | 2001 Apr |
|
Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. | 2001 Apr 20 |
|
Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. | 2001 Apr 6 |
|
The antihyperglycemic effect of estrone sulfate in genetically obese-diabetic (ob/ob) mice is associated with reduced hepatic glucose-6-phosphatase. | 2001 Dec |
|
By the way, Doctor. Whenever I read about the effects of hormone replacement therapy (HRT), the researchers always seem to use 0.625 mg of Premarin. I'm taking 1 mg of Estrace daily. How does this compare to the standard dose of Premarin? | 2001 Dec |
|
Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. | 2001 Dec |
|
By the way, doctor. I've been taking hormone replacement with Premarin and Provera for 12 years. Now that I'm 68 years old, I'd like to stop taking the hormones, but I don't know how. What is the best way to get off HRT? | 2001 Feb |
|
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. | 2001 Feb |
|
Estrogenic potency of chemicals detected in sewage treatment plant effluents as determined by in vivo assays with Japanese medaka (Oryzias latipes). | 2001 Feb |
|
Plasma beta-endorphin levels in obese and non-obese patients with polycystic ovary disease. | 2001 Feb |
|
Synthesis and biological evaluation of two new radiolabelled estrogens: [125I](E)-3-methoxy-17alpha-iodovinylestra-1,3,5(10),6-tetraen-17beta-ol and. | 2001 Feb |
|
Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol. | 2001 Feb 28 |
|
Effects of estrone sulfate alone or with medroxyprogesterone acetate on serum lipoprotein levels in postmenopausal women. | 2001 Jan |
|
Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins. | 2001 Jan |
|
Characteristics of cystic breast disease with special regard to breast cancer development. | 2001 Jan-Feb |
|
Synthesis and reactivity of the catechol metabolites from the equine estrogen, 8,9-dehydroestrone. | 2001 Jun |
|
Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. | 2001 Jun |
|
Fecal analysis of ovarian cycles in female black-handed spider monkeys (Ateles geoffroyi). | 2001 Jun |
|
Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. | 2001 Mar |
|
Sulfation is rate limiting in the futile cycling between estrone and estrone sulfate in enriched periportal and perivenous rat hepatocytes. | 2001 Mar |
|
Follicle-stimulating hormone regulates steroidogenic enzymes in cultured cells of the chick embryo ovary. | 2001 Mar |
|
Endogenous sex hormone levels in postmenopausal women with Alzheimer's disease. | 2001 Mar |
|
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection. | 2001 Mar 16 |
|
Functional analysis and androgen-regulated expression of mouse organic anion transporting polypeptide 1 (Oatp1) in the kidney. | 2001 Mar 19 |
|
Repellent activity of estrogenic compounds toward zoospores of the phytopathogenic fungus Aphanomyces cochlioides. | 2001 Mar-Apr |
|
Actions of the soy phytoestrogen genistein in models of human chronic disease: potential involvement of transforming growth factor beta. | 2001 May |
|
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. | 2001 May 15 |
|
Serum hormones and the alcohol-breast cancer association in postmenopausal women. | 2001 May 2 |
|
Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. | 2001 May-Jun |
|
Endocrinology of gynaecomastia. | 2001 Nov |
|
Micronized progesterone regulation of the endometrial glandular cycling pool. | 2001 Oct |
|
Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. | 2001 Sep |
|
Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. | 2002 Apr |
|
Peripheral changes in estrone sulfate concentration during the first trimester of gestation in cattle: comparison with unconjugated estrogens and relationship to fetal number. | 2002 Apr 15 |
|
Evidence for carrier-mediated transport of unconjugated bilirubin across plasma membrane vesicles from human placental trophoblast. | 2002 Aug |
|
A randomized isoflavone intervention among premenopausal women. | 2002 Feb |
|
The bovine placenta; a source and target of steroid hormones: observations during the second half of gestation. | 2002 Jul |
|
Mammary secretion of oestrogens in the cow. | 2002 Jul |
|
Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. | 2002 Jun 24 |
|
Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. | 2002 Mar |
|
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. | 2002 Mar |
|
Interaction of human organic anion transporters with various cephalosporin antibiotics. | 2002 Mar 8 |
|
The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women. | 2002 May |
|
Formal enantioselective synthesis of (+)-estrone. | 2007 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rxwiki.com/estrone
Curator's Comment: Vaginal route is possible: The recommended dose is 2.0 to 4.0 g intravaginally per day, adjusted to the lowest amount that controls symptoms http://www.rxlist.com/estragyn-drug.htm
Estrone is available in the following doses:
Estrone 2 Mg/ml Intramuscular Solution
Estrone 5 Mg/ml Intramuscular Solution
Estrone Compounding Powder
Forms of Medication
Estrone is available in the following forms:
Injectable Solution
Injectable Suspension
Vaginal Suppository
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11039493
At 1.0 x 10(-8) M, estrone promoted growth of MTW9/PL cells established from the carcinogen-induced hormone-responsive MT-W9A rat mammary tumor of a Wistar-Furth (W/Fu) rat.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
25403-7
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2258-2
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LIVERTOX |
376
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
13739-8
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
WHO-ATC |
G03CA07
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
||
|
LOINC |
22663-9
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
34297-2
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
34299-8
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
31177-9
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
||
|
LOINC |
27998-4
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2257-4
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
6776-9
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
35208-8
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2261-6
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
WHO-ATC |
G03CC04
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
||
|
LOINC |
14160-6
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
34298-0
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2260-8
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2262-4
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
LOINC |
2259-0
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
WHO-VATC |
QG03CA07
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
||
|
CFR |
21 CFR 862.1280
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
||
|
WHO-VATC |
QG03CC04
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ESTRONE
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
53-16-7
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
PRIMARY | |||
|
2DI9HA706A
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1405
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
2DI9HA706A
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
C484
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
SUB07251MIG
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
PRIMARY | |||
|
9699
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
3188
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
100000082364
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
200-164-5
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
2818
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
Estrone (medication)
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
3324
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
D004970
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
5870
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
407
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
17263
Created by
admin on Sat Dec 16 16:02:47 GMT 2023 , Edited by admin on Sat Dec 16 16:02:47 GMT 2023
|
PRIMARY | |||
|
4103
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
m5033
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00655
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
1255001
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY | |||
|
DTXSID4022367
Created by
admin on Sat Dec 16 16:02:48 GMT 2023 , Edited by admin on Sat Dec 16 16:02:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
PARENT (METABOLITE)